News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Anchor Therapeutics Achieves Milestone in GPCR Collaboration


1/10/2011 11:45:58 AM

(BUSINESS WIRE)--Anchor Therapeutics today announced that it has successfully completed the first stage of its collaboration and license agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI). This achievement represents rapid progress for the collaboration, which was launched in September 2010 to develop G protein coupled receptor (GPCR)–targeted therapeutic compounds utilizing Anchor’s proprietary pepducin technology.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES